Literature DB >> 24487689

Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.

Suzanne A W Fuqua1, Guowei Gu, Yassine Rechoum.   

Abstract

The idea that somatic ERα mutations could play an important role in the evolution of hormone-dependent breast cancers was proposed some years ago (Fuqua J Mammary Gland Biol Neoplasia 6(4):407-417, 2001; Dasgupta et al. Annu Rev Med 65:279-292, 2013), but has remained controversial until recently. A significant amount of new data has confirmed these initial observations and shown their significance, along with much additional work relevant to the treatment of breast cancer. Thus, it is the purpose of this review to summarize the research to date on the existence and clinical consequences of ERα mutations in primary and metastatic breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24487689      PMCID: PMC4123761          DOI: 10.1007/s10549-014-2847-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  60 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.

Authors:  Ines Barone; Stefania Catalano; Luca Gelsomino; Stefania Marsico; Cinzia Giordano; Salvatore Panza; Daniela Bonofiglio; Gianluca Bossi; Kyle R Covington; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

Review 3.  Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.

Authors:  R J Santen; R X Song; Z Zhang; R Kumar; M-H Jeng; S Masamura; J Lawrence; L P MacMahon; W Yue; L Berstein
Journal:  J Steroid Biochem Mol Biol       Date:  2005-05       Impact factor: 4.292

Review 4.  Estrogen receptor mutations in human disease.

Authors:  Matthew H Herynk; Suzanne A W Fuqua
Journal:  Endocr Rev       Date:  2004-12       Impact factor: 19.871

5.  American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines.

Authors:  T J Smith; N E Davidson; D V Schapira; E Grunfeld; H B Muss; V G Vogel; M R Somerfield
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

6.  BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.

Authors:  Yongxian Ma; Saijun Fan; Changyan Hu; Qinghui Meng; Suzanne A Fuqua; Richard G Pestell; York A Tomita; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2009-11-03

7.  Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.

Authors:  Ines Barone; Yukun Cui; Matthew H Herynk; Arnoldo Corona-Rodriguez; Cinzia Giordano; Jennifer Selever; Amanda Beyer; Sebastiano Andò; Suzanne A W Fuqua
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

8.  ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression.

Authors:  Jun Sun; Wen Zhou; Kosalai Kaliappan; Zafar Nawaz; Joyce M Slingerland
Journal:  Mol Endocrinol       Date:  2012-08-03

9.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Authors:  R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard
Journal:  Lancet       Date:  2011-12-05       Impact factor: 79.321

10.  Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation.

Authors:  Kathleen Conway; Eloise Parrish; Sharon N Edmiston; Dawn Tolbert; Chiu-Kit Tse; Patricia Moorman; Beth Newman; Robert C Millikan
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  31 in total

Review 1.  The changing role of ER in endocrine resistance.

Authors:  Agostina Nardone; Carmine De Angelis; Meghana V Trivedi; C Kent Osborne; Rachel Schiff
Journal:  Breast       Date:  2015-08-10       Impact factor: 4.380

Review 2.  Anticipatory UPR Activation: A Protective Pathway and Target in Cancer.

Authors:  David J Shapiro; Mara Livezey; Liqun Yu; Xiaobin Zheng; Neal Andruska
Journal:  Trends Endocrinol Metab       Date:  2016-06-25       Impact factor: 12.015

Review 3.  The future of breast cancer systemic therapy: the next 10 years.

Authors:  Melinda L Telli; George W Sledge
Journal:  J Mol Med (Berl)       Date:  2015-01-09       Impact factor: 4.599

Review 4.  Role of epigenetic modifications in luminal breast cancer.

Authors:  Hany A Abdel-Hafiz; Kathryn B Horwitz
Journal:  Epigenomics       Date:  2015-02-17       Impact factor: 4.778

Review 5.  Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Authors:  Shawna B Matthews; Carol A Sartorius
Journal:  Horm Cancer       Date:  2016-10-28       Impact factor: 3.869

Review 6.  Clinical management of breast cancer heterogeneity.

Authors:  Dimitrios Zardavas; Alexandre Irrthum; Charles Swanton; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2015-04-21       Impact factor: 66.675

Review 7.  ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.

Authors:  Rinath Jeselsohn; Gilles Buchwalter; Carmine De Angelis; Myles Brown; Rachel Schiff
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

8.  ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.

Authors:  Luca Gelsomino; Guowei Gu; Yassine Rechoum; Amanda R Beyer; Sasha M Pejerrey; Anna Tsimelzon; Tao Wang; Kenneth Huffman; Andrew Ludlow; Sebastiano Andò; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2016-05-13       Impact factor: 4.872

Review 9.  Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.

Authors:  John A Katzenellenbogen; Christopher G Mayne; Benita S Katzenellenbogen; Geoffrey L Greene; Sarat Chandarlapaty
Journal:  Nat Rev Cancer       Date:  2018-06       Impact factor: 60.716

10.  AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.

Authors:  Yassine Rechoum; Daniela Rovito; Domenico Iacopetta; Ines Barone; Sebastiano Andò; Nancy L Weigel; Bert W O'Malley; Powel H Brown; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2014-09-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.